Results of the PROSPECT trial provide compelling evidence that high-quality preoperative MRI in combination with postoperative analysis of pathologic features can identify a substantial subset of […]

The US Food and Drug Administration (FDA) has approved iptacopan (Fabhalta, Novartis), the first oral monotherapy for both treatment-naive and pretreated adults with paroxysmal nocturnal hemoglobinuria […]

SAN ANTONIO — Breast cancer care can cause significant financial stress for patients, but certain interventions may help patients cope with these financial burdens, new survey […]

TOPLINE: Receiving a poor prognosis after a cancer diagnosis is associated with a greater short-term suicide risk, which is even more pronounced in populations with higher […]

TOPLINE: Commercial health insurance does not necessarily protect cancer patients from potentially devastating out-of-pocket costs. METHODOLOGY: Out-of-pocket costs contribute to financial toxicity in cancer, but little […]

Persistent chemotherapy-related amenorrhea (CRA) after treatment for breast cancer was common and associated with worse long-term quality of life among premenopausal women in a large multicenter […]

TOPLINE: With lower toxicity and equal efficacy, radioimmunotherapy is a better option than autologous stem cell transplant (ASCT) for relapsed /refractory follicular lymphoma consolidation, new data […]